IQAIR TO RELEASE 2024 WORLD AIR QUALITY REPORT, REVEALING CHANGES TO GLOBAL AIR QUALITY AND ITS HEALTH IMPACTS
STEINACH, Switzerland, Feb. 17, 2025 /PRNewswire/ -- On Tuesday, March 11, IQAir will release its highly anticipated 7th annual World Air Quality Report, offering an in-depth analysis of global air pollution trends in 2024. With air pollution remaining the single greatest threat to human and environmental health, this report will uncover troubling new insights about PM2.5 air pollution worldwide.
WHAT: IQAir's 7th annual World Air Quality Report presents a detailed global air pollution analysis, tracking exposure to harmful PM2.5 air pollution across 138 countries, territories, and regions, spanning 8,956 locations. The report is based on data from more than 40,000 air quality monitoring stations worldwide, offering the most comprehensive snapshot of global air pollution to date.
WHEN: The 2024 World Air Quality Report will be publicly released on Tuesday, March 11, at 12:01 a.m. Eastern Time (04:00 UTC). Credentialed journalists can request embargoed access to the report and interviews ahead of the release.
WHY: IQAir's latest findings reveal millions of people continue to breathe polluted air, endangering their health and well-being. The 2024 World Air Quality Report will analyze:
The most polluted countries and cities of 2024
The percentage of countries meeting the World Health Organization's (WHO) annual PM2.5 guideline
The impact of 2024 weather trends on global air pollution
How data was collected and analyzed to uncover key trends
Potential solutions individuals, groups, and governments can take to tackle air pollution problems
WHERE: The full 2024 World Air Quality Report will be available at www.iqair.com/us after the embargo lifts. Embargoed findings and interviews can be requested before the official release.
WHO: The following are available for media interviews on report findings and health impacts of air pollution:
Frank Hammes, Global CEO, IQAir
Glory Dolphin Hammes, CEO North America, IQAir
Dr. Christi Chester Schroeder, Air Quality Science Manager, IQAir
HOW: To request embargoed report findings or an embargoed interview, contact Armen Araradian at pr.na@iqair.com.
ABOUT IQAir:
IQAir is a Swiss technology company that empowers individuals, organizations, and governments to improve air quality through information, collaboration, and intervention.
For press inquiries, interviews, and media coverage please contact:
Armen Araradianpr.na@iqair.com+1 (562) 315-6010
View original content to download multimedia:https://www.prnewswire.com/news-releases/iqair-to-release-2024-world-air-quality-report-revealing-changes-to-global-air-quality-and-its-health-impacts-302376013.html
SOURCE IQAir
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review
STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST study evaluates exidavnemab, a drug candidate being developed as a treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort in the ongoing clinical Phase 2a study EXIST evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson's disease. An interim safety review showed that exidavnemab was safe and well tolerated. The positive outcome will result in the initiation of two further cohorts, to evaluate a higher dose of exidavnemab in comparison with placebo in patients with Parkinson's disease as well as MSA. "Exidavnemab is BioArctic's second disease modifying treatment for severe brain diseases, building on a similar scientific approach as Leqembi®. Both originate from our antibody platform, selectively targeting aggregated, toxic misfolded proteins. I am pleased that the interim safety review of our phase 2a study EXIST of exidavnemab showed a good safety and tolerability profile as expected, supporting progression into higher doses in both Parkinson's disease and MSA," says Gunilla Osswald, CEO at BioArctic. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic profile. In addition, a broad range of biomarkers will be evaluated in plasma, cerebrospinal fluid (CSF), and using digital measurements. Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as Parkinson's disease and MSA. Exidavnemab is a monoclonal antibody (mAb) that selectively targets pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregated alpha-synuclein damages nerve cells, and by selectively binding and removing these aggregates, exidavnemab is intended to preserve nerve cell function and slow the disease. There is a large unmet medical need for slowing disease progression in diseases such as Parkinson's disease and MSA. Exidavnemab has recently been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of MSA. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on June 13, 2025, at 08:00 CET. For further information, please contact:Oskar Bosson, VP Communications and Investor RelationsE-mail: mailto: +46 70 410 71 80 About Exidavnemab Exidavnemab is a monoclonal antibody drug candidate that is designed to selectively target and eliminate pathological alpha-synuclein aggregates, while sparing the physiological forms. Aggregates of alpha-synuclein participate in neurodegenerative disorders including Parkinson's disease and Multiple System Atrophy (MSA). The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with exidavnemab is ongoing since 2024. EXIST is an important step towards a proof-of-concept study focusing on the efficacy of the drug candidate. Exidavnemab has been granted orphan drug designation (ODD) in the US and a positive opinion regarding orphan medicinal product designation (OD) in the EU for the treatment of Multiple System Atrophy (MSA). About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit This information was brought to you by Cision The following files are available for download: BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review View original content: SOURCE BioArctic Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment. The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia. Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO. With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer's disease. About Merry Life Biomedical Company Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs. Media ContactDr. Ih-Jen SuMerry Life Biomedical Company, +886-910-902-296Email: suihjen0704@ View original content to download multimedia: SOURCE Merry Life Biomedical Company, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Taiwan Goes All-In for BIO in Boston: 2025's Pavilion Promotes Biotech Innovation, Tech Power, and Global Partnerships
BOSTON, June 11, 2025 /PRNewswire/ -- Taiwan's delegation, led by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office), organized by the Ministry of Economic Affairs, and supported by various government agencies, will attend the BIO International Convention 2025, taking place June 16–19 in Boston. The Taiwan Pavilion, themed "Taiwan, Your Best Partner in Asia," brings together 35 companies, one industry association, and six research institutes to showcase advancements in AI-driven healthcare, biomanufacturing, and precision medicine. Building on BIO 2024's success with 19,608 attendees and 61,508 business matchmaking meetings, Taiwan aims to strengthen its role as a global biotech leader by highlighting innovations and expanding international partnerships. The Taiwan Pavilion highlights "Full-Age Precision Medicine," showcasing over 50 technologies addressing healthcare needs across all life stages. Key innovations - Taiwan's expertise in AI enhances medical informatics and smart healthcare solutions, while its biomanufacturing supports global pharmaceutical production. These advancements position Taiwan as a leader in regenerative medicine, medical devices, and contract development and manufacturing organizations (CDMOs). Adding further momentum to Taiwan's presence at the convention, two Taiwanese biotech startups — AnHorn Medicines and Pharmasaga Company Limited — have been selected as finalists in the Start-Up Stadium, a global competition that drew 57 teams from around the world. Their selection reflects the rising profile and competitiveness of Taiwan's biotech sector and provides finalists with a valuable opportunity to engage with global pharmaceutical leaders and venture capitalists, potentially leading to strategic partnerships and funding opportunities. Taiwan's BIO 2025 Key Events to Attend – Tuesday, June 17 Global Innovation Hub – Taiwan (3:15–3:30 p.m., Meeting Room 152):A focused session spotlighting Taiwan's biomedical breakthroughs and collaboration opportunities, reflecting the broad coalition behind Taiwan's delegation across industry, government, academia, and clinical sectors. Taiwan Pavilion Networking Event (4:00–5:00 p.m., Booths 1545 & 1645):An open networking event welcoming global biotech leaders, featuring a Happy Hour and showcasing next-generation technologies, promising products, and emerging opportunities for cross-border collaboration. The Taiwan Pavilion at BIO 2025 (Booth No. 1545 & 1645) showcases numerous biotech companies. Coordinated by BPIPO, it promotes global partnerships in biotech, CDMO, and precision health. Exhibited technologies include cell and gene therapy, novel drug development, smart medical devices, and integrated solutions for all stages of healthcare. As BIO 2025 approaches, Taiwan's delegation prepares to showcase its biotech strengths and global strategy to shape the industry's future. More details and delegation links are available at or by contacting BPIPO. View original content to download multimedia: SOURCE The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) Sign in to access your portfolio
